Frazier Healthcare Partners
Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, &a; medical products.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Frazier Healthcare Partners Information
Geographic Data
Address: 601 Union Street
City: Seattle
State: WA
Zip: 98101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$6B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,885,569Website Global Rank
5,860Website Monthly Traffic
Twitter Followers
Description
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Contact Phone:
+12066217200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 11/2007 | Zonare Medical Systems | Series G | 30M |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 11/2006 | Bariatric Partners | Series B | 0 |
| 1/2000 | ZymoGenetics | Funding Round | - |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 9/2020 | Trillium Therapeutics | Post-IPO Equity | 25M |
| 12/2009 | EBR Systems | Venture Round | 15M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 5/2016 | Aptinyx | Series A | 0 |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 1/2006 | Xoft | Series C | 0 |
| 7/2010 | BARRX Medical | Series D | 15M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 12/2004 | Barosense | Series B | 6.2M |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 1/2021 | Avadel Pharmaceuticals | Post-IPO Equity | - |
| 3/2013 | AcertaPharma | Series A | 60M |
| 4/2020 | Dascena | Series B | 50M |
| 2/2000 | PatientKeeper | Series A | 8.6M |
| 10/2005 | EBR Systems | Series B | 21M |
| 1/1998 | Array BioPharma | Venture Round | - |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 2/2011 | Chimerix | Series F | 45M |
| 10/2021 | Scout Bio | Series B | 0 |
| 1/2017 | The CORE Institute | Private Equity Round | - |
| 2/2000 | Xenoport | Series A | 15.9M |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 7/2008 | Collegium Pharmaceutical | Series D | 0 |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 1/2020 | Epizyme | Post-IPO Equity | - |
| 1/2000 | Simpata Inc | Series B | 20M |
| 1/1991 | Tularik | Funding Round | - |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 2/2019 | Recida Therapeutics | Series A | 8.5M |
| 10/2007 | Zeltiq Aesthetics | Series B | 20.3M |
| 1/2020 | IVERIC bio | Post-IPO Equity | - |
| 5/2007 | CVRx | Series D | 65M |
| 1/1996 | ViroPharma | Funding Round | - |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 7/2011 | PowerVision | Series C | 24M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 9/2000 | Zonare Medical Systems | Series B | 9.5M |
| 12/2007 | Barosense | Series C | 11.2M |
| 12/2020 | Sutro Biopharma | Post-IPO Equity | 144.9M |
| 11/2009 | Calibra Medical | Venture Round | 1.4M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 6/2004 | EBR Systems | Series A | 5.2M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 11/2017 | Mavupharma | Series A | 0 |
| 2/2009 | Primaeva Medical | Series C | 6M |
| 1/1997 | OraPharma Inc. (acquired by JNJ) | Venture Round | - |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 12/2017 | Aptinyx | Series B | 70M |
| 4/2001 | Fast Track | Series C | 0 |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 11/2020 | Inipharm | Series A | 0 |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 8/2003 | Zonare Medical Systems | Series D | 6.5M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 3/2019 | Scout Bio | Series B | 20M |
| 4/2010 | Achaogen | Series C | 56M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 12/2007 | PowerVision | Series B | 20M |
| 6/2016 | Alpine Immune Sciences | Series A | 48M |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 10/2021 | Radionetics Oncology | Private Equity Round | 30M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 1/2014 | Ignyta | Debt Financing | 10M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 1/2020 | Galera Therapeutics | Venture Round | - |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 6/2008 | EBR Systems | Series C | 35M |
| 1/2019 | Sojournix | Series C | 44M |
| 3/2017 | Vaxcyte | Series B | 60M |
| 7/2008 | CVRx | Series E | 0 |
| 9/2019 | Passage Bio | Series B | 110M |
| 8/2008 | Glaukos | Series D | 35M |
| 7/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 15M |
| 5/2007 | Marcadia Biotech | Series A | 15M |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 1/2012 | Moximed | Venture Round | 1.8M |
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 2/2007 | Chimerix | Series D | 23.1M |
| 3/2020 | Vaxcyte | Series D | 0 |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 7/2020 | MBX Biosciences | Series A | 34.6M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 11/2009 | Calypso Medical | Series E | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 8/2000 | PatientKeeper | Series B | 0 |
| 8/2008 | Calibra Medical | Series B | 35M |
| 4/2017 | Cirius Therapeutics | Series A | 0 |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 9/2013 | PreCision Dermatology | Debt Financing | 67M |
| 6/2005 | Cierra | Funding Round | 21M |
| 8/2018 | Cirius Therapeutics | Series A | 9M |
| 5/2020 | Lengo Therapeutics | Series A | 15M |
| 11/2007 | AnaptysBio | Series B | 0 |
| 10/2005 | QuatRx Pharmaceuticals | Series D | 17M |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 10/2003 | Cotherix | Series C | 55M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 6/2003 | Xoft | Series B | 0 |
| 7/2015 | AnaptysBio | Series D | 40M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 8/2009 | Barosense | Series D | 27M |
| 7/2013 | Alcresta | Series B | 10M |
| 7/2004 | Zonare Medical Systems | Series E | 34M |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 6/2016 | Iovance Biotherapeutics | Equity | 100M |
| 3/2020 | Amunix | Series A | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 4/2007 | Xoft | Series D | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 8/2008 | PatientKeeper | Series F | 0 |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 4/2008 | Stromedix | Series B | 25M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 6/2004 | PatientKeeper | Series D | 0 |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 2/2008 | Zonare Medical Systems | Equity | 30M |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 2/2021 | Seraxis | Series C | 40M |
| 9/2021 | HilleVax | Equity | 135M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 1/2007 | Calixa Therapeutics | Funding Round | - |
| 2/2007 | Pivot Medical | Series A | 2M |
| 1/2020 | Bellus Health | Post-IPO Equity | - |
| 3/2006 | PowerVision | Series A | 2M |
| 1/2023 | Curve Beam | Funding Round | 0 |
| 3/2006 | Zeltiq Aesthetics | Series A | 7.5M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 6/2010 | Incline Therapeutics | Series A | 43M |
| 8/2018 | Krystal Biotech | Post-IPO Equity | 10M |
| 12/2003 | FlowCardia | Series B | 12M |
| 3/2009 | Stemgent | Series B | 14M |
| 4/2017 | Arcutis Biotherapeutics | Series A | 13.5M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 20M |
| 1/2018 | ARMO BioSciences | Venture Round | - |
| 2/2021 | ESSA Pharma | Post-IPO Equity | 130M |
| 9/2002 | Glaukos | Series A | 10M |
| 1/2013 | Scilex Holding Company | Venture Round | - |
| 8/2015 | Calibrium | Convertible Note | 1.7M |
| 1/2014 | PowerVision | Series D | 0 |
| 1/2002 | QuatRx Pharmaceuticals | Series B | 2M |
| 1/2022 | Metagenomi | Series B | 0 |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 3/2021 | Amunix | Series B | 117M |
| 1/2006 | Primaeva Medical | Series A | 1.3M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 1/2008 | Ascension Orthopedics | Series D | 21M |
| 8/2007 | FlowCardia | Series C | 0 |
| 1/1996 | Corixa | Venture Round | - |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 12/2006 | Primaeva Medical | Series B | 7M |
| 12/2004 | QuatRx Pharmaceuticals | Series D | 15M |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 6/2006 | PatientKeeper | Series E | 0 |
| 1/2005 | PowerVision | Series A | 4.4M |
| 11/2011 | Allena Pharmaceuticals | Series A | 15M |
| 6/2017 | Alteon Health | Private Equity Round | - |
| 1/2020 | REGENXBIO | Post-IPO Equity | - |
| 5/2011 | Silvergate Pharmaceuticals | Venture Round | 23.6M |
| 4/2012 | Alcresta | Series A | 10M |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 3/2007 | Stromedix | Series A | 1M |
| 12/2007 | Pivot Medical | Series B | 0 |
| 7/2002 | Barosense | Series A | 6.2M |
| 1/1993 | VIVUS | Venture Round | - |
| 12/2020 | Rocket Pharmaceuticals | Post-IPO Equity | 299M |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 1/2021 | Aclaris Therapeutics | Post-IPO Equity | - |
| 3/2020 | Molecular Templates | Post-IPO Debt | 45M |
| 1/1991 | CV Therapeutics | Funding Round | - |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 8/2021 | Immunovant | Corporate Round | 200M |
| 1/2022 | Metagenomi | Series B | 0 |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 0 |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 0 |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
| 9/2021 | HilleVax | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
